1. The description of the objectives in the abstract is very different to the description provided in the introduction (page 7).
2. Inclusion criteria: please specify range of lung function values (pre or post-bronchodilator) and smoking habits. Will you accept never smokers in the study? Any age restriction? Any exclusion due to comorbidities? The criteria in general should be more clearly explained.
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GENERAL COMMENTS
Goertz and colleagues present a protocol for a novel and interesting study, which will provide much needed data on fatigue in COPD and hopefully raise the profile of this neglected symptom. The protocol is informative and clear. The authors provide a rationale for their design choices. There is an extensive battery of secondary outcome measures, but I note the use of adaptive/electronic questionnaires that will ensure missing data is minimized.
A few specific comments:
The sample size makes no mention of moderate fatigue, whereas the exposure of interest appears to be moderate-to-severe fatigue. I appreciate this is presented as an example of a 3-group classification, but the change in terminology was noted.
The timing of the peri-hospitalisation measure is stated as the 'first days of…' If this time point has been operationalised it would be useful to specify more clearly.
A key strength of the prospective design is that is enables you to assess the 'temporality' of associations between fatigue and your outcomes. The key points under strengths and limitations (page 3 in footnote), and the strengths in the discussion (page 12) could specify this more clearly.
Under secondary outcomes use of an iPod is stated -do you mean iPad ? FAntasTIGUE study.
REVIEWER
-Please remove the conclusions section, as this is not part of journal format for protocol articles.
o Pag. 14: The conclusion section has been removed.
-You have cited reference number 33 to 66 in table 1 prior to reference number 29 which makes your citations incorrect. Please review again your main document and ensure that all references will be cited and will appear in ascending order.
o We have revised the references throughout the complete manuscript, they appear now in ascending order.
-We have implemented an additional requirement to all articles to include 'Patient and Public Involvement' statement within the main text of your main document.
o Page 5/6: We added information on the patient and public involvement.
Patient and public involvement
Based on the input of patients with chronic lung disease, fatigue was prioritized as a research topic during the Netherlands Respiratory Society (NRS) meeting (www.nationaalprogrammalongonderzoek.nl).
[18] As stated, patient representatives
Reviewer(s) Reports:
Reviewer: 1
Thanks for giving me the opportunity to review this manuscript describing an interesting protocol to evaluate fatigue in COPD. The manuscript is informative and well written. There are only a few aspects that should be improved.
First of all, we would like to thank the reviewer -Marc Miravitlles-for his feedback on this manuscript.
We have taken the suggestions to heart and have revised the following:
C1 The description of the objectives in the abstract is very different to the description provided in the introduction (page 7).
R1 For consistency, the objectives in the abstract are aligned with the objectives in the introduction.
The primary aim objectives of this study areis to chart the course of fatigue in patients with COPD, to identify the physical, systemic, psychological, and behavioural factors that precipitate and perpetuate fatigue in patients with COPD, . Moreover, the secondary aim is to evaluate the impact of exacerbation-related hospitalizations on fatigue, and to better understand the association between fatigue and 2-year all-cause hospitalization and mortality in patients with COPD. Moreover, the secondary aim is to identify diurnal differences in fatigue by using Ecological Momentary Assessment (EMA).
By adding these objectives, we exceeded the word limit (300 words). Therefore, we had to make some minor changes in the abstract.
C2 Inclusion criteria: please specify range of lung function values (pre or post -bronchodilator)
and smoking habits. Will you accept never smokers in the study? Any age restriction? Any exclusion due to comorbidities? The criteria in general should be more clearly explained.
R2
We have elaborated on the inclusion criteria.
To be eligible, a subject must meet the following criteria: ii. No exacerbation-related hospitalization less than 4 weeks preceding enrolment;
iii. No use of oral corticosteroids and/or antibiotics less than 4 weeks preceding enrolment;
iv. Provided written informed consent.
Patients lacking a sufficient understanding of the Dutch language and/or participating in concurrent intervention studies will be excluded. There are no age or smoking status restrictions, as well as no exclusion based on comorbidities or the use of long term oxygen therapy.
Reviewer: 2
Goertz and colleagues present a protocol for a novel and interesting study, which will provide much needed data on fatigue in COPD and hopefully raise the profile of this neglected symptom. The protocol is informative and clear. The authors provide a rationale for their design choices. There is an extensive battery of secondary outcome measures, but I note the use of adaptive/electronic questionnaires that will ensure missing data is minimized. A few specific comments:
We are grateful to reviewer 2 -Matthew Maddocks-for his feedback and we will now react to the suggestions provided:
C1 The sample size makes no mention of moderate fatigue, whereas the exposure of interest appears to be moderate-to-severe fatigue. I appreciate this is presented as an example of a 3-group classification, but the change in terminology was noted.
R1 For consistency in terminology, moderate fatigue has been changed into mild fatigue (throughout the complete manuscript). This is in accordance with the terminology used by the developers of the CIS-Fatigue checklist (normal, mild, severe fatigue, respectively).
C2
R2 In order to specify the time of the hospitalization measure, the following is added:
a. Pag. 6: The assessments at baseline, 12 months, and during the first four days of a possible exacerbation-related hospitalization will be performed in a hospital setting.
b. Pag. 6: Also, when patients are admitted to the hospital between baseline and 12 months due to an exacerbation of COPD, some tests will be repeated during the first four days of hospitalization, and to weeks after discharge.
C3 A key strength of the prospective design is that is enables you to assess the 'temporality' of associations between fatigue and your outcomes. The key points under strengths and limitations (page 3 in footnote), and the strengths in the discussion (page 12) could specify this more clearly.
R3
The strength "to investigate whether the associations between fatigue and the explaining factors are temporarily or fluctuate over time" has been added to the pages:
